| Name | Title | Contact Details |
|---|---|---|
Matt Lasmanis |
Chief Information Officer | Profile |
Adam Stein |
Director, Corporate Counsel | Profile |
Nicole Victoria |
Associate Director, Quality Compliance | Profile |
Nicole Victoria |
Associate Director, Quality Compliance | Profile |
William Pezzolo |
Director, Corporate Counsel | Profile |
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company`s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic "off-the-shelf" cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Solstice Neurosciences is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.